Table 4 Clinical outcome with respect to systemic treatment modality. Patients from the literature supplemented by our patient. N = 55
Treatment modality | Outcome | ||
|---|---|---|---|
Auditory | Ocular | Other | |
No of patients (%) | |||
No systemic treatment N = 11/55 (20) | Deaf: 7/11 (64) Moderately impaired: 3/11 (27) Remission: 0/11 (0) | Recurrences 2/11 (18) Remission 6/11 (55) | Death 1/11 (9) Arthritis 1/11 (9) |
Systemic CS N = 14/55 (25) | Deaf/severely impaired: 6/14 (43) Complete/partial remission: 8/14 (57) | Impaired vision 2/14 (14) Remission 11/14 (79) | Arthritis 1/14 (7) |
Systemic CS and cDMARDs N = 26/55 (47) | Deaf/severely impaired 11/26 (42) Moderately impaired: 7/26 (27) Complete/partial remission: 7/26 (27) | Impaired vision: 3/26 (12) Recurrences: 4/26 (15) Secondary complications: 2/26 (8) Remission: 14/26 (54) | Death 1/26 (4) Vestibular 2/26 (8) Vascular 1/26 (4) Renal 2/26 (8) |
Systemic CS, cDMARD and biologics N = 2/55 (4) | Severely impaired 1/2 (50) Complete/partial remission: ½ (50) | Decreased vision: 1/2 (50) Remission: ½ (50) | None |
Systemic CS and colchicine N = 2/55 (4) | Deaf/severely impaired: 2/2 (100) | Decreased vision: ½ (50) Remission: ½ (50) | Vestibular: ½ (50) |